Insmed Incorporated
Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company founded in 1988 and headquartered in Bridgewater, New Jersey, focuses on rare diseases with investigational and approved therapies in pulmonary, inflammatory, and other serious conditions; its approved products include ARIKAYCE (amikacin liposome inhalation suspension) for Mycobacterium avium complex lung disease in adults with limited treatment options and BRINSUPRI (brensocatib), a first-in-class neutrophil elastase inhibitor for non-cystic fibrosis bronchiectasis; the company advances a pipeline encompassing TPIP for pulmonary arterial hypertension, INS1201, and preclinical programs in gene therapy, AI-driven protein engineering, RNA end-joining, and synthetic rescue, serving patients primarily through clinical trials and commercial launches targeting chronic lung diseases. Insmed operates 9 corporate offices and 4 global research sites across the United States, Europe, Japan, and other regions, with over 1,500 employees as of mid-2025. Recent developments include FDA approval of BRINSUPRI in 2025 and its subsequent European Union approval, topline results from the Phase 2b pulmonary arterial hypertension study and Phase 3 ASPEN study in 2024-2025, the opening of a new research lab in Cambridge, UK, a proposed $650 million public offering of common stock in June 2025, raised full-year 2025 ARIKAYCE revenue guidance to $420-430 million, and repeated recognition as the No. 1 biopharma employer by Science magazine.
Company News
Insmed Appoints Two New Directors to Its Board
Insmed Launches BRINSUPRI® Tablets 25 mg (brensocatib hydrate) for the Treatment of Non-Cystic Fibrosis Bronchiectasis in Japan
Insmed Features the Global Phase 3 PALM Clinical Development Program Evaluating Treprostinil Palmitil Inhalation Powder (TPIP) at CHEST 2026
Insmed to Present New Data Across Its Respiratory Portfolio at CHEST 2026 and IDWeek 2026
Perpetual Ltd Acquires 5,760 Shares of Insmed, Inc. $INSM
This Insmed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
INSM Stock Slides on CFO Exit, Reiterates '26 Sales View
Insmed Stock Slides — CFO Exit Date Set, 2026 Guidance Reaffirmed
Insmed Announces CFO Transition
3 Healthcare Stocks Showing Why the Sector Still Has Momentum
FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce
Insmed: Expensive Stock, But Discount To Recent Highs Makes Bull Case
FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027
Insmed Expands Community Impact During Fifth Annual Global Day of Good
Insmed Incorporated (INSM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Insmed Incorporated (INSM) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Insmed: A Strong Launch And A Much Bigger Peak Sales Opportunity
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026
Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now?